Literature DB >> 1560202

Human monoclonal antibody homodimers. Effect of valency on in vitro and in vivo antibacterial activity.

E A Wolff1, J Esselstyn, G Maloney, H V Raff.   

Abstract

Human IgG1 mAb dimers specific for either group B streptococci or Escherichia coli K1 bacteria were formed using chemical cross-linkers. The effect of antibody valency on biologic efficacy was investigated by comparing the IgG dimers against the corresponding IgG monomers. Binding activity and relative avidity were assessed using Ag binding and competition ELISA, and functional activity was analyzed using opsonophagocytic assays. These in vitro assays revealed that the dimers were greater than or equal to 50-fold more active than the monomers. A neonatal rat infection model showed the in vivo protective efficacy of the dimers was greater than or equal to 20-fold greater than that of the monomers. Enhancing the activity of mAb by chemical cross-linking may be a useful strategy for salvaging low affinity IgG mAb that possess poor functional properties.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1560202

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  4 in total

Review 1.  Bacterial carbohydrates in neonatal sepsis: targets for immunotherapy.

Authors:  H V Raff
Journal:  Springer Semin Immunopathol       Date:  1993

Review 2.  Cooperative binding by mouse IgG3 antibodies: implications for functional affinity, effector function, and isotype restriction.

Authors:  N S Greenspan; L J Cooper
Journal:  Springer Semin Immunopathol       Date:  1993

3.  Complement-independent binding of microorganisms to primate erythrocytes in vitro by cross-linked monoclonal antibodies via complement receptor 1.

Authors:  J H Powers; B L Buster; C J Reist; E Martin; M Bridges; W M Sutherland; R P Taylor; W M Scheld
Journal:  Infect Immun       Date:  1995-04       Impact factor: 3.441

4.  Protective murine monoclonal antibodies to Cryptococcus neoformans.

Authors:  J Mukherjee; M D Scharff; A Casadevall
Journal:  Infect Immun       Date:  1992-11       Impact factor: 3.441

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.